BioNTech SE is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
BioNTech news
23.06.2022
BioNTech has begun construction of an mRNA vaccine manufacturing plant in Kingali, Rwanda. The approximately 30,000-square-meter facility will be equipped with two BioNTainers. One will be used to produce mRNA vaccines and the other to handle the finished product. The first unit is planned to be delivered by the end of 2022. Production at the facility will s...
Source: 
investors.biontech.de
investors.biontech.de
09.05.2022
BioNTech's IFRS net profit for 3 months of 2022 amounted to €3.699 billion, up 3.28 times from €1.128 billion in the previous year. Revenue increased 3.11 times to €6.375 billion from €2.048 billion a year earlier.
Source: investors.biontech.de
investors.biontech.de
30.03.2022
The BioNTech Board of Directors has proposed a special dividend of $2 per share. The last day to purchase securities to receive the dividend is May 30, 2022. The annual dividend yield could be 1.16%.
Source: investors.biontech.de
investors.biontech.de
30.03.2022
BioNTech's IFRS net income for 2021 was €10.293 billion, up many times over from €0.015 billion the previous year. Revenue increased 39.4 times to €18.977 billion from €0.482 billion a year earlier.
Source: investors.biontech.de
investors.biontech.de
General information
| Company name | BioNTech |
|---|---|
| Tags | #coronavirus, #vaccines |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | An der Goldgrube 12 Mainz, 55131 Germany |
| Website | investors.biontech.de |
| Information disclosure | www.sec.gov |
English (US) 